Evidence map›Paper›PMID 42774851›Full record

ArticleRSC advances2026

Sorafenib-loaded porphyrin-phospholipid liposomes for enhanced chemophototherapy in hepatocellular carcinoma.

Meiling Tian, Jing Wang, Ming Gao, Chaoyuan Xia, Jing Xiao, Yi Zhao, Bingjie Han, Ningjing Lei, Siyuan Huang, Baihui Xie and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Meiling TianTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.ORCID https://orcid.org/0009-0000-2072-4434
Jing WangTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.ORCID https://orcid.org/0009-0004-5085-516X
Ming GaoTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.ORCID https://orcid.org/0009-0007-9497-2810
Chaoyuan XiaTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.ORCID https://orcid.org/0009-0001-7072-2733
Jing XiaoTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.
Yi ZhaoTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.
Bingjie HanTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.
Ningjing LeiDepartment of Microbiology and Immunology, School of Basic Medical Sciences, Zhengzhou University Zhengzhou 450052 Henan China.
Siyuan HuangTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.ORCID https://orcid.org/0009-0004-1495-8890
Baihui XieTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.ORCID https://orcid.org/0009-0006-3737-7153
Lulu HeDepartment of Biological Sample Bank, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.
Fazhan WangTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.ORCID https://orcid.org/0000-0003-4708-1816
Shengnan MaDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.ORCID https://orcid.org/0000-0001-9100-1831
Bo QinTranslational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University Zhengzhou 450052 Henan China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sorafenib (SF) remains a frontline chemotherapeutic agent for treating hepatocellular carcinoma (HCC). However, its clinical utility is severely hampered by systemic toxicity and the rapid emergence of drug resistance. To overcome these challenges, we developed a liposomal nanoplatform co-encapsulating SF and a porphyrin-phospholipid conjugate (2HPoP) for combined chemo-photodynamic therapy. The synthesized SF-loaded 2HPoP liposomes (2HPoP lip@SF) exhibited favorable physicochemical characteristics, including high encapsulation efficiency, colloidal stability, and prolonged storage stability. Upon 665 nm red-light laser irradiation, 2HPoP lip@SF demonstrated controlled drug release and robust reactive oxygen species (ROS) generation, enabling synergistic antitumor effects.

Identifiers

PMID42774851
PMCPMC13595587

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.